Literature DB >> 27647907

Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.

Paul E Leon1, Wenqian He1, Caitlin E Mullarkey2, Mark J Bailey1, Matthew S Miller3, Florian Krammer2, Peter Palese4, Gene S Tan4.   

Abstract

Influenza virus strain-specific monoclonal antibodies (mAbs) provide protection independent of Fc gamma receptor (FcγR) engagement. In contrast, optimal in vivo protection achieved by broadly reactive mAbs requires Fc-FcγR engagement. Most strain-specific mAbs target the head domain of the viral hemagglutinin (HA), whereas broadly reactive mAbs typically recognize epitopes within the HA stalk. This observation has led to questions regarding the mechanism regulating the activation of Fc-dependent effector functions by broadly reactive antibodies. To dissect the molecular mechanism responsible for this dichotomy, we inserted the FLAG epitope into discrete locations on HAs. By characterizing the interactions of several FLAG-tagged HAs with a FLAG-specific antibody, we show that in addition to Fc-FcγR engagement mediated by the FLAG-specific antibody, a second intermolecular bridge between the receptor-binding region of the HA and sialic acid on effector cells is required for optimal activation. Inhibition of this second molecular bridge, through the use of an F(ab')2 or the mutation of the sialic acid-binding site, renders the Fc-FcγR interaction unable to optimally activate effector cells. Our findings indicate that broadly reactive mAbs require two molecular contacts to possibly stabilize the immunologic synapse and potently induce antibody-dependent cell-mediated antiviral responses: (i) the interaction between the Fc of a mAb bound to HA with the FcγR of the effector cell and (ii) the interaction between the HA and its sialic acid receptor on the effector cell. This concept might be broadly applicable for protective antibody responses to viral pathogens that have suitable receptors on effector cells.

Entities:  

Keywords:  Fcγ receptor; antibody-dependent cell-mediated immunity; broadly reactive antibodies; hemagglutinin; influenza virus

Mesh:

Substances:

Year:  2016        PMID: 27647907      PMCID: PMC5056099          DOI: 10.1073/pnas.1613225113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice.

Authors:  Oscar Medina-Contreras; Duke Geem; Oskar Laur; Ifor R Williams; Sergio A Lira; Asma Nusrat; Charles A Parkos; Timothy L Denning
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

2.  Generation of recombinant influenza virus from plasmid DNA.

Authors:  Luis Martínez-Sobrido; Adolfo García-Sastre
Journal:  J Vis Exp       Date:  2010-08-03       Impact factor: 1.355

3.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

4.  Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells.

Authors:  O Mandelboim; N Lieberman; M Lev; L Paul; T I Arnon; Y Bushkin; D M Davis; J L Strominger; J W Yewdell; A Porgador
Journal:  Nature       Date:  2001-02-22       Impact factor: 49.962

5.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

6.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

Review 7.  The biology of influenza viruses.

Authors:  Nicole M Bouvier; Peter Palese
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

8.  A cellular receptor of human rhinovirus type 2, the very-low-density lipoprotein receptor, binds to two neighboring proteins of the viral capsid.

Authors:  Emmanuelle Neumann; Rosita Moser; Luc Snyers; Dieter Blaas; Elizabeth A Hewat
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Characterization of variable-region genes and shared crossreactive idiotypes of antibodies specific for antigens of various influenza viruses.

Authors:  T M Moran; M Monestier; A C Lai; G Norton; M A Reale; M A Thompson; J L Schulman; R Riblet; C A Bona
Journal:  Viral Immunol       Date:  1987       Impact factor: 2.257

10.  Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors.

Authors:  Susan E Chisholm; Keith Howard; Mar Valés Gómez; Hugh T Reyburn
Journal:  J Infect Dis       Date:  2007-03-02       Impact factor: 5.226

View more
  74 in total

Review 1.  B Cell Activation and Response Regulation During Viral Infections.

Authors:  Jonathan H Lam; Fauna L Smith; Nicole Baumgarth
Journal:  Viral Immunol       Date:  2020-04-23       Impact factor: 2.257

2.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

3.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Authors:  Guha Asthagiri Arunkumar; Andriani Ioannou; Teddy John Wohlbold; Philip Meade; Sadaf Aslam; Fatima Amanat; Juan Ayllon; Adolfo García-Sastre; Florian Krammer
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 4.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

Review 5.  Inactivated influenza virus vaccines: the future of TIV and QIV.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Curr Opin Virol       Date:  2017-05-12       Impact factor: 7.090

6.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

7.  Antibody Determinants of Influenza Immunity.

Authors:  James E Crowe
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

8.  Differential requirements for FcγR engagement by protective antibodies against Ebola virus.

Authors:  Stylianos Bournazos; David J DiLillo; Arthur J Goff; Pamela J Glass; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 9.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

10.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.